Audentes Therapeutics, Inc. (NASDAQ:BOLD) CEO Matthew R. Patterson sold 15,000 shares of the stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $300,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Audentes Therapeutics, Inc. (BOLD) traded up 5.68% during trading on Friday, reaching $17.50. 257,481 shares of the company’s stock were exchanged. The stock’s market cap is $383.06 million. Audentes Therapeutics, Inc. has a 12-month low of $13.13 and a 12-month high of $22.82. The company has a 50 day moving average of $19.92 and a 200 day moving average of $16.80.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.10. Equities research analysts anticipate that Audentes Therapeutics, Inc. will post ($3.46) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Matthew R. Patterson Sells 15,000 Shares of Audentes Therapeutics, Inc. (BOLD) Stock” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/12/matthew-r-patterson-sells-15000-shares-of-audentes-therapeutics-inc-bold-stock-updated-updated-updated.html.

Several hedge funds and other institutional investors have recently modified their holdings of BOLD. Jennison Associates LLC boosted its position in shares of Audentes Therapeutics by 182.4% in the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after buying an additional 546,617 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Audentes Therapeutics by 31.5% in the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after buying an additional 153,617 shares during the last quarter. Northern Trust Corp boosted its position in shares of Audentes Therapeutics by 238.0% in the second quarter. Northern Trust Corp now owns 184,173 shares of the biotechnology company’s stock valued at $3,524,000 after buying an additional 129,681 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new position in shares of Audentes Therapeutics during the second quarter valued at about $2,870,000. Institutional investors and hedge funds own 57.52% of the company’s stock.

A number of analysts recently weighed in on the stock. ValuEngine lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Wedbush reissued an “ourperform” rating and issued a $20.00 price objective on shares of Audentes Therapeutics in a research report on Monday, May 15th. Finally, Leerink Swann assumed coverage on shares of Audentes Therapeutics in a research report on Monday, May 1st. They issued an “outperform” rating and a $22.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $22.25.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Stock Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related stocks with our FREE daily email newsletter.